After a delay in England for its new lung cancer med Tagrisso, AstraZeneca on Tuesday won some reprieve from the country’s cost watchdogs. The AZ drug, dubbed a "breakthrough" therapy by the FDA, will be the first available through the revamped Cancer Drugs Fund.
Will Entresto be the megablockbuster that was expected? Early numbers say it isn't so. But Novartis has reason to believe, according to some talk at ESC this week.
Pharma companies are discovering that developing apps and digital health technologies is just like developing drugs--at least when it comes to persuading payers to cover them.